Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

TPCA-1

🥰Excellent
Catalog No. T3049Cas No. 507475-17-4
Alias TPCA1, IKK2 Inhibitor IV, GW683965

TPCA-1 (TPCA1) is an effective and specific IKK-2 inhibitor (IC50: 17.9 nM); shows >22-fold selectivity over IKK-1 and >550-fold selectivity over others kinases and enzymes.

TPCA-1

TPCA-1

🥰Excellent
Purity: 99.29%
Catalog No. T3049Alias TPCA1, IKK2 Inhibitor IV, GW683965Cas No. 507475-17-4
TPCA-1 (TPCA1) is an effective and specific IKK-2 inhibitor (IC50: 17.9 nM); shows >22-fold selectivity over IKK-1 and >550-fold selectivity over others kinases and enzymes.
Pack SizePriceAvailabilityQuantity
2 mg$38In Stock
5 mg$61In Stock
10 mg$97In Stock
25 mg$175In Stock
50 mg$288In Stock
100 mg$446In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "TPCA-1"

Select Batch
Purity:99.29%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
TPCA-1 (TPCA1) is an effective and specific IKK-2 inhibitor (IC50: 17.9 nM); shows >22-fold selectivity over IKK-1 and >550-fold selectivity over others kinases and enzymes.
Targets&IC50
IKK2:17.9 nM
In vitro
TPCA-1 significantly reduces collagen-induced T-cell proliferation in vivo. Administering TPCA-1 (3/10/20 mg/kg, i.p., b.i.d.) prophylactically results in a dose-dependent reduction in the severity of collagen-induced arthritis (CIA) in mice. Specifically, TPCA-1 at 20 mg/kg (i.p., b.i.d.) markedly decreases the severity of CIA, an effect comparable to that of etanercept (12.5 mg/kg, i.p.) administered every other day. Additionally, TPCA-1 at 10 mg/kg (i.p., b.i.d.) significantly diminishes disease severity and delays disease onset, mirroring the efficacy of etanercept (4 mg/kg, i.p.) given every other day as a preventive measure.
In vivo
TPCA-1 exhibits concentration-dependent inhibition of TNF-α (IC50: 170 nM), IL-6 (IC50: 290 nM), and IL-8 (IC50: 320 nM) production. It also suppresses the proliferation of glioma cells, TNF-induced nuclear translocation of RelA (p65), and NFκB-dependent IL8 gene expression. Furthermore, TPCA-1 inhibits gene expression induced by IFN, completely blocks the expression of the MX1 and GBP1 genes, and has a minimal effect on ISG15 expression. Additionally, TPCA-1 demonstrates inhibition of IKK-1 (IC50: 400 nM) and JNK3 (IC50: 3600 nM).
Kinase Assay
IKK-2 Assay: Recombinant human IKK-2 (residues 1-756) is expressed in baculovirus as an N-terminal GST-tagged fusion protein, and its activity is assessed using a time-resolved fluorescence resonance energy transfer assay. In brief, IKK-2 (5 nM final) diluted in assay buffer (50 mM HEPES, 10 mM MgCl2, 1 mM CHAPS, pH 7.4, with 1 mM DTT and 0.01% w/v BSA) is added to wells containing various concentrations of compound or dimethyl sulfoxide (DMSO) vehicle (3% final). The reaction is initiated by the addition of GST-IκBα substrate (25 nM final)/ATP (1 μM final), in a total volume of 30 μL. The reaction is incubated for 30 min at room temperature, then terminated by the addition of 15 μL of 50 mM EDTA. Detection reagent (15 μL) in buffer (100 mM HEPES, pH 7.4, 150 mM NaCl, and 0.1% w/v BSA) containing antiphosphoserine- IκBα-32/36 monoclonal antibody 12C2, labeled with W-1024 europium chelate, and an allophycocyanin-labeled anti-GST antibody is added, and the reaction is further incubated for 60 min at room temperature. The degree of phosphorylation of GST- IκBαis measured as a ratio of specific 665-nm energy transfer signal to reference europium 620-nm signal, using a Packard Discovery plate reader.
Cell Research
Ten microliters of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from stock solution (10?mg/mL) is added to each well of 96-well plates containing glioma cells and incubated at 37 °C for 2–4?h. Oxidized MTT is solubilized by adding 100?μL of 10% sodium dodecyl sulfate (SDS) in 0.01?N HCL, and plates are incubated at 37 °C for 4?h in a humidified chamber. Plates are read at 570?nm on a plate reader.(Only for Reference)
AliasTPCA1, IKK2 Inhibitor IV, GW683965
Chemical Properties
Molecular Weight279.29
FormulaC12H10FN3O2S
Cas No.507475-17-4
SmilesNC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1
Relative Density.1.491g/cm3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
H2O: Insoluble
Ethanol: 2.8 mg/mL (10 mM)
DMSO: 1 mg/mL, Sonication is recommended.
Solution Preparation Table
Ethanol
1mg5mg10mg50mg
1 mM3.5805 mL17.9025 mL35.8051 mL179.0254 mL
5 mM0.7161 mL3.5805 mL7.1610 mL35.8051 mL
10 mM0.3581 mL1.7903 mL3.5805 mL17.9025 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy TPCA-1 | purchase TPCA-1 | TPCA-1 cost | order TPCA-1 | TPCA-1 chemical structure | TPCA-1 in vivo | TPCA-1 in vitro | TPCA-1 formula | TPCA-1 molecular weight